Zendy
Open Access
FDA Expands Zytigaʼs Use for Late-Stage Prostate Cancer
Oncology Times2013Journals
FDA expanded the approved use of abiraterone acetate (Zytiga, Jannsen Bioech) to treat men with late-stage castration-resistant prostate cancer prior to receiving chemotherapy.

The content you want is available to Zendy users.

Already have an account? Sign in
Having issues? Contact support